GILEAD SCIENCES, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.6 USD | +1.59% |
|
+1.15% | -19.12% |
| 05-07 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
| 05-02 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
| Sales 2024 * | 27.6B 2,206B | Sales 2025 * | 28B 2,237B | Capitalization | 80.53B 6,436B |
|---|---|---|---|---|---|
| Net income 2024 * | 403M 32.21B | Net income 2025 * | 6.35B 508B | EV / Sales 2024 * | 3.58 x |
| Net Debt 2024 * | 18.15B 1,451B | Net Debt 2025 * | 12.68B 1,014B | EV / Sales 2025 * | 3.33 x |
| P/E ratio 2024 * |
183
x | P/E ratio 2025 * |
12.4
x | Employees | 18,000 |
| Yield 2024 * |
4.79% | Yield 2025 * |
5.04% | Free-Float | 99.92% |
More Fundamentals
* Assessed data
More news
Latest transcript on Gilead Sciences, Inc.
More recommendations
More press releases
| 1 day | +1.59% | ||
| 1 week | +1.15% | ||
| Current month | +0.50% | ||
| 1 month | -3.81% | ||
| 3 months | -11.99% | ||
| 6 months | -13.69% | ||
| Current year | -19.12% |
1 week
64.34
66.14
1 month
64.3369.03
Current year
64.3387.87
1 year
64.3387.87
3 years
57.1789.74
5 years
56.5689.74
10 years
56.56123.37
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 59 | 28/02/19 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 31/12/15 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 11/04/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 69 | 16/10/20 |
| Director/Board Member | 71 | 31/12/17 | |
Ted Love
BRD | Director/Board Member | 65 | 01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.99% | 0 M€ | +11.86% | - | |
| 8.10% | 0 M€ | 0.00% | - | |
| 8.06% | 0 M€ | 0.00% | - | |
| 5.23% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/05/24 | 65.52 | +1.46% | 2 128 804 |
| 09/05/24 | 64.58 | -0.52% | 6,048,572 |
| 08/05/24 | 64.92 | -0.82% | 5,134,980 |
| 07/05/24 | 65.46 | -0.12% | 7,318,161 |
| 06/05/24 | 65.54 | +1.17% | 7,187,265 |
Delayed Quote Nasdaq, May 10, 2024 at 03:18 pm
More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
14/05/2024
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.58
USD
Average target price
82.93
USD
Spread / Average Target
+28.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.12% | 80.53B | |
| +32.12% | 695B | |
| +26.51% | 568B | |
| -4.59% | 361B | |
| +19.79% | 330B | |
| +3.79% | 283B | |
| +16.68% | 239B | |
| +8.37% | 204B | |
| -7.61% | 198B | |
| +8.55% | 168B |
- Stock Market
- Equities
- GILD Stock
